Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XH-5102
- Development stage
- Unknown
- Lead developer
- Chengdu Jinruijiye Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XH-5102 is an orally administered small molecule inhibitor of Janus kinase 2 (JAK2) developed by Shanghai Xunhe Pharmaceutical Technology. It is currently in Phase I/II clinical development for the treatment of various myeloproliferative neoplasms (MPNs), including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET). The drug targets the JAK-STAT signaling pathway, which is frequently dysregulated in MPNs, often due to mutations like JAK2 V617F. XH-5102 is being evaluated for its safety, tolerability, and preliminary efficacy in patients with these conditions, regardless of their JAK2 mutation status.
- Other names
- XH-5102XH5102XH 5102
02
Targets
Beyond the preview
Go deeper on XH-5102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XH-5102.